Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
BCR-ABL mutant kinetics in CML patients treated with dasatinib.
Nicolini FE, Chabane K, Tigaud I, Michallet M, Magaud JP, Hayette S. Nicolini FE, et al. Among authors: hayette s. Leuk Res. 2007 Jun;31(6):865-8. doi: 10.1016/j.leukres.2006.12.003. Epub 2007 Jan 8. Leuk Res. 2007. PMID: 17208297 Clinical Trial.
Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone.
Nicolini FE, Hayette S, Legros L, Rousselot P, Maloisel F, Tulliez M, Guerci A, Charbonnier A, Prébet T, Rigal-Huguet F, Chabane K, Magaud JP, Paillet C, Pivot C, Michallet M. Nicolini FE, et al. Among authors: hayette s. Leuk Res. 2011 Jan;35(1):80-6. doi: 10.1016/j.leukres.2010.04.010. Epub 2010 Jun 3. Leuk Res. 2011. PMID: 20605207 Clinical Trial.
The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge.
Nicolini FE, Chomel JC, Roy L, Legros L, Chabane K, Ducastelle S, Nicolas-Virelizier E, Michallet M, Tigaud I, Magaud JP, Turhan A, Guilhot F, Hayette S. Nicolini FE, et al. Among authors: hayette s. Clin Lymphoma Myeloma Leuk. 2010 Oct;10(5):394-9. doi: 10.3816/CLML.2010.n.073. Clin Lymphoma Myeloma Leuk. 2010. PMID: 21030353
Immunoarchitectural patterns in splenic marginal zone lymphoma: correlations with chromosomal aberrations, IGHV mutations, and survival. A study of 76 cases.
Traverse-Glehen A, Bachy E, Baseggio L, Callet-Bauchu E, Gazzo S, Verney A, Hayette S, Jallades L, Ffrench M, Salles G, Coiffier B, Felman P, Berger F. Traverse-Glehen A, et al. Among authors: hayette s. Histopathology. 2013 May;62(6):876-93. doi: 10.1111/his.12092. Histopathology. 2013. PMID: 23611359
Major molecular response achievement in CML Patients can be predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS ratio at an earlier time point of follow-up than currently recommended.
Huet S, Cony-Makhoul P, Heiblig M, Tigaud I, Gazzo S, Belhabri A, Souche D, Michallet M, Magaud JP, Hayette S, Nicolini F. Huet S, et al. Among authors: hayette s. PLoS One. 2014 Sep 9;9(9):e106250. doi: 10.1371/journal.pone.0106250. eCollection 2014. PLoS One. 2014. PMID: 25203717 Free PMC article.
117 results